The North America Exosome Diagnostic and Therapeutic Market would witness market growth of 25.9% CAGR during the forecast period (2022-2028).
The rise in the prevalence of chronic disease, infectious disease, autoimmune disease, and cancer, as well as the spike in demand for molecular diagnosis, are driving the exosome diagnostic and therapeutic market. Furthermore, recent advancements in exosome technology in drug development and discovery provide vital information about heterogeneity and biological function, enhancing the possibility to leverage the therapeutic and diagnostic potential of exosomes in cancer and infectious disease. As a result, advancements in healthcare technology are propelling the growth of the exosome diagnostic and therapeutic market.
Exosomes derived from cow milk are being used to deliver therapeutic compounds to patients suffering from lung and breast cancer. Due to their tiny size, indigenous character, and capacity to traverse biological barriers, exosomes produced from specific body regions are intriguing candidates for anti-cancer vaccinations due to better passive targeting. As a result, as the number of cancer cases in hospitals rises, so will the demand for exosomes in diagnostics and therapies.
The North American region is one of the most flourishing exosome markets because of its strong healthcare infrastructure, effective government policies, a large base of multinational enterprises, and high public knowledge about diagnostics and healthcare. A huge number of government-funded research studies have been undertaken on the role of exosome-based medications in diseases such as melanoma, breast cancer, lung cancer, and pancreatic cancer, to name a few. Several colleges, including Yale University and Michigan State University, have financed and worked with companies like Merck and Exosome Diagnostic to perform clinical trials in the United States. Furthermore, government funding is very supportive of these projects. These will propel the North American exosome diagnostic and therapeutic market.
The US market dominated the North America Exosome Diagnostic and Therapeutic Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $391.1 million by 2028. The Canada market is anticipated to grow at a CAGR of 28.7% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 27.6% during (2022 - 2028).
Based on Application, the market is segmented into Diagnostic and Therapeutic. Based on Product, the market is segmented into Reagent, Instrument, and Software. Based on End User, the market is segmented into Cancer Institute, Hospital, Diagnostic Center, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Exosome Diagnostic and Therapeutic Market is Estimated to reach $1.4 Billion by 2028, at a CAGR of 26.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.
By Application
By Product
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 